Report Publication Announcement • Mar 28, 2014
Report Publication Announcement
Open in ViewerOpens in native device viewer
Paris, March 28, 2014 – BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products, announced that it will participate in the Smallcap Event, a forum dedicated to meetings between institutional investors and listed companies from the Euronext Zone, on Monday 7th and Tuesday 8th of April 2014 in Paris (Pullman Tour Eiffel Hotel).
During these two days, BioAlliance Pharma Management team will meet with institutional investors to present the Company and its development strategy.
Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases. The Company has also successfully developed products based on its innovative muco-adhesive Lauriad® technology both registered in Europe and in the United States. Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the U.S.
BioAlliance Pharma has developed an advanced product portfolio:
Livatag® (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going Validive® (Clonidine Lauriad® ) (mucositis): Phase II on going AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2012 Reference Document filed with the AMF on April 18, 2013, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (www.bioalliancepharma.com).
Judith Greciet, CEO [email protected] Nicolas Fellmann, CFO [email protected] +33 1 45 58 76 00
Caroline Carmagnol +33 6 64 18 99 59 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.